Around the world the incidence of cancer is growing, and with it the demand for better, faster and cheaper solutions to diagnosis and treat.
Current techniques for cancer staging are limited by the availability of the radioactive tracers used for sentinel lymph node biopsy (SLNB), now regarded as best practice in the treatment of breast cancer. Of more than 500,000 breast cancer patients in the West that could benefit from the procedure, only around 50% have access to SLNB. This figure drops to 5% in China, and is minimal in most of the rest of the world.
Endomagnetics has introduced an exciting new technology to overcome this issue with a system based on magnetic materials rather than radioisotopes. The SentiMag® and its magnetic tracer, Sienna+®, allow for best practice to be used globally, with lower costs and reduced workflow complexity, and leaving surgeons fully in control of the procedure. Sienna+® magnetic tracers require no special preparation and handling, making for more efficient workflow.
The Endomagnetics solution provides much-needed flexibility and control in the fight against breast cancer. Melanoma and colorectal cancer sufferers are also likely to benefit from this exciting technological advance.
Endomagnetics was founded to solve cancer staging and healthcare challenges through the application of advanced magnetic sensing technology and nanotechnology, and the company is developing a portfolio of medical device products based on a patented ability to detect magnetic materials in the human body with exceptional sensitivity. The technology was originally developed at University College London and the University of Houston.